{"organizations": [], "uuid": "aeccd0c320bcf67e7a14bb91d4299e34f0c59394", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180301.html", "section_title": "Archive News &amp; Video for Thursday, 01 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-idera-pharma-announces-launch-of-p/brief-idera-pharma-announces-launch-of-phase-3-trial-evaluating-imo-2125-in-combination-with-ipilimumab-idUSASB0C896", "country": "US", "domain_rank": 408, "title": "Idera Pharma Announces Launch Of Phase 3 Trial Evaluating IMO-2125 In Combination With Ipilimumab", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.451, "site_type": "news", "published": "2018-03-01T20:13:00.000+02:00", "replies_count": 0, "uuid": "aeccd0c320bcf67e7a14bb91d4299e34f0c59394"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-idera-pharma-announces-launch-of-p/brief-idera-pharma-announces-launch-of-phase-3-trial-evaluating-imo-2125-in-combination-with-ipilimumab-idUSASB0C896", "ord_in_thread": 0, "title": "Idera Pharma Announces Launch Of Phase 3 Trial Evaluating IMO-2125 In Combination With Ipilimumab", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "idera pharma", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "idera pharmaceuticals inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 1 (Reuters) - Idera Pharmaceuticals Inc:\n* IDERA PHARMACEUTICALS ANNOUNCES LAUNCH OF GLOBAL PHASE 3 TRIAL EVALUATING IMO-2125 IN COMBINATION WITH IPILIMUMAB FOR THE TREATMENT OF ANTI-PD-1 REFRACTORY MELANOMA (ILLUMINATE 301) Source text for Eikon: (Reuters.Brief@thomsonreuters.com)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-01T20:13:00.000+02:00", "crawled": "2018-03-02T19:41:33.005+02:00", "highlightTitle": ""}